Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Oral Clofarabine in Myelodysplastic Syndrome (MDS)

Trial Profile

Phase II Study of Oral Clofarabine in Myelodysplastic Syndrome (MDS)

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2015

At a glance

  • Drugs Clofarabine (Primary)
  • Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Dec 2012 Results presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
    • 10 Dec 2012 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
    • 15 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top